New data from the JUPITER study demonstrated that CRESTOR (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels. Results also showed that for patients in the trial taking rosuvastatin: the combined risk of heart attack, stroke or CV death was reduced by nearly half (47%, p<0.001). risk of heart attack was cut by more than...